MDS Nordion Begins to Manufacture Cardiac Imaging Agent



    
    Bracco's Cardiogen-82(R) Enables Cardiologists to Better Detect
    Cardiovascular Disease
    

    OTTAWA, June 10 /CNW/ - MDS Nordion, a leading provider of medical
isotopes and radiopharmaceuticals, today announced that it has commenced the
manufacture of CardioGen-82(R) (Rubidium-82 generators), for Bracco
Diagnostics, Inc. (part of Bracco Group), one of the world's leading companies
in the imaging agent business.
    MDS Nordion has designed and built a dedicated manufacturing suite within
its world-class, U.S. Food and Drug Administration (FDA)-approved, Good
Manufacturing Practices (GMP)-compliant production facility in Ottawa.
Production of CardioGen-82 began yesterday.
    CardioGen-82, the only generator-based, cardiac Positron Emission
Tomography (PET) perfusion imaging agent approved by the FDA, produces
Rubidium-82, using a specialized generator technology. Once administered to
the patient, Rubidium-82 is used as a PET imaging tracer for perfusion studies
of the heart to examine blood flow through heart vessels. PET is a highly
sensitive medical imaging technique that produces a three-dimensional image of
the functioning heart, allowing the cardiologist to identify regions of the
heart muscle receiving poor blood flow.
    "There is growing interest in advanced molecular imaging technologies to
help better diagnose and treat disease," said Steve West, President of MDS
Nordion. "MDS Nordion provides a full spectrum of services for the development
and commercialization of novel radiopharmaceuticals. For more than 10 years,
companies like Bracco have been relying on our proven track record for
innovative solutions, quality, and reliability that make MDS Nordion the
partner of choice."
    A 2007 Frost & Sullivan report entitled U.S. PET and PET-CT (Computerized
Tomography) Imaging Equipment Markets indicated that use of PET imaging as a
diagnostic tool is on the rise. For the period 2007-2014, the report projects
a total compounded annual growth rate of 17.3% for PET and PET-CT.
    "This is an important milestone in the development of Bracco's innovative
cardiac imaging technology and the new MDS facility provides Bracco with a
world-class manufacturing capability with significant capacity for future
expansion to meet anticipated market growth," said Carlo Medici, President and
Chief Executive Officer of Bracco Diagnostics, Inc. "MDS Nordion's unique
expertise in the development and manufacture of radiopharmaceuticals, along
with its highly specialized facilities, made them an obvious choice when
Bracco looked to expand its CardioGen-82 production capacity."
    MDS Nordion offers tailored solutions, leading expertise and service
capabilities for radiopharmaceutical development, clinical and commercial
manufacturing, and radiation-based medical device development. MDS Nordion has
GMP-compliant facilities in Ottawa and Vancouver, Canada, and Fleurus, Belgium
that can accommodate a variety of development, manufacturing, and supply
requirements.

    About Bracco Imaging S.p.A.

    Bracco Imaging S.p.A. is one of the world's leading companies in the
diagnostic imaging business. Bracco Imaging develops, manufactures, and
markets diagnostic imaging agents and solutions that meet medical needs and
facilitate clinical solutions. Headquartered in Milan, Italy, Bracco Imaging
operates in over 80 markets worldwide, either directly or indirectly, through
subsidiaries, joint ventures, licenses, and distribution partnership
agreements.
    Bracco Imaging is a subsidiary of Bracco S.p.A., the holding company of
the Bracco Group which also markets ethical and over-the-counter (OTC)
pharmaceutical products in Italy as well as advanced medical technology
systems worldwide. Furthermore, the Bracco Group offers diagnosis services
through the Milan-based Centro Diagnostico Italiano (Italian Diagnostic
Center). For more information, visit www.braccoimaging.com.

    About MDS Nordion

    MDS Nordion, a business unit of MDS Inc., is a global leader in providing
medical isotopes for molecular and diagnostic imaging, radiotherapeutics, and
sterilization technologies for medical products that benefit the lives of
millions of people in more than 50 countries around the world. MDS Nordion
products and services are used on a daily basis by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals, clinics, and
research laboratories. Find out more at www.mdsnordion.com

    About MDS

    MDS Inc. (TSX: MDS; NYSE:   MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research, medical isotopes
for molecular imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.





For further information:

For further information: MEDIA: Shelley Maclean, (613) 592-3400, ext.
2414, shelley.maclean@mdsinc.com; INVESTORS: Kim Lee, (416) 213-4721,
kim.lee@mdsinc.com

Organization Profile

MDS NORDION

More on this organization

Nordion Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890